Cardiovascular DiseaseNCT02536456
China PEACE Million Persons Project
An observational study of Cardiovascular Disease, run by China National Center for Cardiovascular Diseases at 1 site in China.
Trial summary
China PEACE Millions Persons Project is a national screening project for cardiovascular disease in China. This Project was approved by National Health and Family Planning Commission (NHFPC), China and founded by Ministry of Finance, China in 2014. The specific objectives of the project are to: 1. Read more about this study
- Who is it for?
- Ages 35 to 75 yearsHealthy volunteers can take part
- Conditions the study is for
- Cardiovascular Disease
- How many people
- 4,000,000 participants
- Where
- 1 siteChina
- Study dates
- Jul 2014to Jul 2021
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 35 to 75 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Residents from the communities or villages in selected sites
Who may be able to join
- 35 - 75 years old
- registered in the Hukou of the selected region
- sign the consent form
Who cannot join
- -
Trial locations and contacts
1 site in 1 country.
China1 site, 1 recruiting
- Recruiting
Fuwai hospital
Beijing, Beijing Municipality
Lixin Jiang, MD, PhD, 8610-8839-6203, lixin.jiang@fwoxford.org
Lixin Jiang, MD, PhD
About this study
China PEACE Millions Persons Project is a national screening project for cardiovascular disease in China. This Project was approved by National Health and Family Planning Commission (NHFPC), China and founded by Ministry of Finance, China in 2014.
The specific objectives of the project are to:
- identify subjects at high-risk of CVD and provide counseling for medication and lifestyle improvements
- evaluate the feasibility of such screening methods for subjects at high risk of CVD, and to assess the effect of health counseling on CVD incidence rates and risk factors control
- inform future intervention and long-term follow up efforts for primary and secondary CVD prevention in China.
- Conditions
- Cardiovascular Disease
- Keywords
- screening, counseling, follow-up, cardiovascular disease, population-based project, China
- Medical subject headings
- Cardiovascular Diseases
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of Cardiovascular diseases
Number of new cardiovascular diseases in high-risk subjects
Measured: 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Aug 2015 (estimated)
- Study startJul 2014
- Primary completionJul 2021 (estimated)
- Study completionJul 2021 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (6)Papers the sponsor has linked to this study.
- Other trials for Cardiovascular DiseaseStudies of the same condition, open and under way.
- More trials run by China National Center for Cardiovascular DiseasesThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 4,000,000 participants (estimated)
Sponsor and investigators
- Sponsor type
- Other government
- Responsible party
- Sponsor
- Investigators
- Lixin Jiang, MD, PhD, Principal investigator, China National Center for Cardiovascular Diseases
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02536456
- Sponsor's protocol ID
- 20150823
- Status last verified
- Aug 2020
- First submitted
- 24 Aug 2015
- Last updated
- 17 Aug 2020
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Liu X, Lin S, Zhang H, Zhang X, Wu C, Chen B, Yang Y, Cui J, Xu W, Song L, Yang H, He W, Zhang Y, Li X, Lu J. Association of HDL subclass components with all-cause and cardiovascular mortality: a prospective cohort study based on the ChinaHEART project. Lipids Health Dis. 2026 Jan 27;25(1):63. doi: 10.1186/s12944-026-02874-w.
PubMed 41593465Wu S, Feng X, Zheng H, Wang J, Yan M, Zhou D, Feng Y. Sex-Specific Association of Left Ventricular Hypertrophy With Cardiovascular Events in High-Risk of Cardiovascular Disease Population: Findings From the Sub-Cohort of China PEACE Million Persons Project. J Clin Hypertens (Greenwich). 2025 May;27(5):e70072. doi: 10.1111/jch.70072.
PubMed 40400489Wang Y, Peng K, Xu W, Huang X, Liu X, Li Y, Lu J, Yang Y, Chen B, Shi Y, Han G, Zhang X, Cui J, Song L, Tian A, Runsi W, Wang C, Tian Y, Wu Y, Lin C, Peng W, Li X, Hu S. Cardiovascular disease-specific and all-cause mortality across socioeconomic status and lifestyles among patients with established cardiovascular disease in communities of China: data from a national population-based cohort. Heart. 2025 Oct 29;111(22):1092-1100. doi: 10.1136/heartjnl-2024-324766.
PubMed 40081938Wang R, Wang Y, Lu J, Li Y, Wu C, Yang Y, Cui J, Xu W, Song L, Yang H, He W, Zhang Y, Zhang X, Li X, Hu S. Forecasting cardiovascular disease risk and burden in China from 2020 to 2030: a simulation study based on a nationwide cohort. Heart. 2025 Feb 12;111(5):205-211. doi: 10.1136/heartjnl-2024-324650.
PubMed 39638429China PEACE Collaborative Group; Zhou T, Wang Y, Zhang H, Wu C, Tian N, Cui J, Bai X, Yang Y, Zhang X, Lu Y, Spatz ES, Ross JS, Krumholz HM, Lu J, Li X, Hu S. Primary care institutional characteristics associated with hypertension awareness, treatment, and control in the China PEACE-Million Persons Project and primary health-care survey: a cross-sectional study. Lancet Glob Health. 2023 Jan;11(1):e83-e94. doi: 10.1016/S2214-109X(22)00428-4.
PubMed 36521957Lu J, Xuan S, Downing NS, Wu C, Li L, Krumholz HM, Jiang L. Protocol for the China PEACE (Patient-centered Evaluative Assessment of Cardiac Events) Million Persons Project pilot. BMJ Open. 2016 Jan 4;6(1):e010200. doi: 10.1136/bmjopen-2015-010200.
PubMed 26729395
Study at a glance
From the registry record, last updated by the sponsor on 17 Aug 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- China PEACE Million Persons Project
- ClinicalTrials.gov ID
- NCT02536456
- Acronym / sponsor ID
- 20150823
- Conditions
- Cardiovascular Disease
- Keywords
- screening, counseling, follow-up, cardiovascular disease, population-based project, China
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 4,000,000 participants (estimated)
- Lead sponsor
- China National Center for Cardiovascular DiseasesOther government
- Study start
- Jul 2014
- Primary completion
- Jul 2021 (estimated)
- Study completion
- Jul 2021 (estimated)
- First posted
- 31 Aug 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
China PEACE Millions Persons Project is a national screening project for cardiovascular disease in China. This Project was approved by National Health and Family Planning Commission (NHFPC), China and founded by Ministry of Finance, China in 2014.
The specific objectives of the project are to:
- identify subjects at high-risk of CVD and provide counseling for medication and lifestyle improvements
- evaluate the feasibility of such screening methods for subjects at high risk of CVD, and to assess the effect of health counseling on CVD incidence rates and risk factors control
- inform future intervention and long-term follow up efforts for primary and secondary CVD prevention in China.
Study design
- Observational model
- Other
- Time perspective
- Prospective
Who may qualify
- Ages
- 35 to 75 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Residents from the communities or villages in selected sites
Key inclusion criteria (3 listed)
- 35 - 75 years old
- registered in the Hukou of the selected region
- sign the consent form
Key exclusion criteria (1 listed)
- -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Incidence of Cardiovascular diseases
Time frame: 5 years
Number of new cardiovascular diseases in high-risk subjects
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Aug 2020.
- Derived from this study: PubMed 41593465Liu X, Lin S, Zhang H, Zhang X, Wu C, Chen B, Yang Y, Cui J, Xu W, Song L, Yang H, He W, Zhang Y, Li X, Lu J. Association of HDL subclass components with all-cause and cardiovascular mortality: a prospective cohort study based on the ChinaHEART project. Lipids Health Dis. 2026 Jan 27;25(1):63. doi: 10.1186/s12944-026-02874-w.
- Derived from this study: PubMed 40400489Wu S, Feng X, Zheng H, Wang J, Yan M, Zhou D, Feng Y. Sex-Specific Association of Left Ventricular Hypertrophy With Cardiovascular Events in High-Risk of Cardiovascular Disease Population: Findings From the Sub-Cohort of China PEACE Million Persons Project. J Clin Hypertens (Greenwich). 2025 May;27(5):e70072. doi: 10.1111/jch.70072.
- Derived from this study: PubMed 40081938Wang Y, Peng K, Xu W, Huang X, Liu X, Li Y, Lu J, Yang Y, Chen B, Shi Y, Han G, Zhang X, Cui J, Song L, Tian A, Runsi W, Wang C, Tian Y, Wu Y, Lin C, Peng W, Li X, Hu S. Cardiovascular disease-specific and all-cause mortality across socioeconomic status and lifestyles among patients with established cardiovascular disease in communities of China: data from a national population-based cohort. Heart. 2025 Oct 29;111(22):1092-1100. doi: 10.1136/heartjnl-2024-324766.
- Derived from this study: PubMed 39638429Wang R, Wang Y, Lu J, Li Y, Wu C, Yang Y, Cui J, Xu W, Song L, Yang H, He W, Zhang Y, Zhang X, Li X, Hu S. Forecasting cardiovascular disease risk and burden in China from 2020 to 2030: a simulation study based on a nationwide cohort. Heart. 2025 Feb 12;111(5):205-211. doi: 10.1136/heartjnl-2024-324650.
- Derived from this study: PubMed 36521957China PEACE Collaborative Group; Zhou T, Wang Y, Zhang H, Wu C, Tian N, Cui J, Bai X, Yang Y, Zhang X, Lu Y, Spatz ES, Ross JS, Krumholz HM, Lu J, Li X, Hu S. Primary care institutional characteristics associated with hypertension awareness, treatment, and control in the China PEACE-Million Persons Project and primary health-care survey: a cross-sectional study. Lancet Glob Health. 2023 Jan;11(1):e83-e94. doi: 10.1016/S2214-109X(22)00428-4.
- Derived from this study: PubMed 26729395Lu J, Xuan S, Downing NS, Wu C, Li L, Krumholz HM, Jiang L. Protocol for the China PEACE (Patient-centered Evaluative Assessment of Cardiac Events) Million Persons Project pilot. BMJ Open. 2016 Jan 4;6(1):e010200. doi: 10.1136/bmjopen-2015-010200.
Related trials for Cardiovascular Disease
Active, not recruitingPhase 3
ENDOTHELION Study Group: Effect of Bosentan in NAION Patients
Ischemic Optic Neuropathy
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Not yet recruitingPhase 2
Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma (RRMM)
RecruitingPhase 2
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
Multiple Myeloma
Recruiting
PAW-Hydrogel for Chronic Wound Healing
Diabetic Foot Ulcer (DFU), Pressure Ulcer (PU)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Lixin Jiang, MD, PhD principal investigator
China National Center for Cardiovascular Diseases
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cardiovascular Disease, run by China National Center for Cardiovascular Diseases at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 17 Aug 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Jiapeng Lu, PhD (0086-10-60866783, jiapeng.lu@fwoxford.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of Cardiovascular diseases (time frame: 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02536456, which also lists 6 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Aug 2020.